Atrial fibrillation is increasingly common, 1 with more than 800 000 people being affected in England. 2 Many people are managed in primary care without hospital involvement. The condition is a major cause of morbidity, particularly stroke, and it reduces life expectancy. Strokes caused by atrial fibrillation are largely avoidable-most can be prevented by anticoagulation. Yet uptake of anticoagulation by people with known atrial fibrillation who are at increased risk of stroke is suboptimal. [3] [4] [5] Since the publication of the 2006 guidance, several developments relating to risk stratification, stroke prevention, and rhythm management have led to a partial update on the 2006 guidance. This article summarises the most recent recommendations from the National Institute for Health and Care Excellence (NICE). 6 Recommendations NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the Guideline Development Group's experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets. All recommendations below should be in accordance with the NICE patient experience guideline, 7 and the benefits and risks of treatment should be discussed with the patient.
Diagnosis and assessment
• Perform manual pulse palpation to assess for the presence of an irregular pulse, which might be indicative of underlying atrial fibrillation in people presenting with any of the following: breathlessness or dyspnoea, palpitations, syncope or dizziness, chest discomfort, stroke or transient ischaemic attack. (Recommendation from 2006 guideline.)
• Perform electrocardiography (ECG) in all people, whether symptomatic or not, in whom atrial fibrillation is suspected because an irregular pulse has been detected. 
Drug treatments to prevent stroke (figure )
The guideline revision emphasises that people at very low risk, who should not receive an anticoagulant, should be identified first, with anticoagulation considered or offered to the remainder, taking bleeding risk into account. Anticoagulation may be with a non-vitamin K antagonist oral anticoagulant (apixaban, dabigatran etexilate, or rivaroxaban, in accordance with individual NICE appraisals [11] [12] [13] ) or a vitamin K antagonist (such as warfarin).
• Do not offer stroke prevention treatment to people aged under 65 years with atrial fibrillation and no risk factors other than their sex (that is, very low risk of stroke equating to CHA 2 DS 2 -VASc score of 0 for men or 1 for women 
Review of stroke and anticoagulant risk
All people with atrial fibrillation should undergo review at least annually.
• 
Rate and rhythm control
There is currently no evidence that rhythm management is superior to rate control in preventing stroke or reducing mortality. The main treatment objective is therefore control of symptoms.
• Offer rate control as the first line strategy to people with atrial fibrillation except for those in whom a rhythm control strategy would be more suitable on the basis of clinical judgment (these include people with new onset atrial fibrillation or atrial fibrillation with a reversible cause 
Non-pharmacological management of rate and rhythm
Left atrial ablation is an effective option when drug management has failed. Ablation treatment has a better outcome when undertaken earlier rather than later and for paroxysmal rather than persistent atrial fibrillation. Pacing followed by atrioventricular node ablation is an alternative to left atrial ablation. Pacing followed by atrioventricular node ablation does not restore sinus rhythm but successfully limits ventricular rate.
Overcoming barriers
Anticoagulation is underused in the management of atrial fibrillation. 4 5 In older people in particular, aspirin is often used in preference to anticoagulation, 3 even though anticoagulation has been shown to reduce stroke rates by about 50% in this population, compared with aspirin. 15 We believe the new guideline deals with these problems through paradigm change, identifying low risk people in whom anticoagulation is not indicated, and making it clear that aspirin is no longer considered a cost effective alternative.
Further information on the guidance
An update to the existing guideline was necessary as a result of changes in anticoagulant practice and developments in the pharmacological and interventional management of people with atrial fibrillation.
Methods
The Guideline Development Group (GDG) comprised four cardiologists (including the chair), two general practitioners, two patient representatives, an emergency medicine consultant, a consultant in general and geriatric medicine, a pharmacist, and two specialist nurses. The GDG also co-opted a consultant cardiothoracic surgeon and a consultant haematologist.
The GDG followed the standard NICE methods in the development of this guideline. 16 The group developed clinical questions; collected and appraised clinical evidence; and evaluated the cost effectiveness of proposed interventions through literature review and original economic modelling.
Quality ratings of the evidence were based on GRADE methodology. 17 These relate to the quality of the available evidence for assessed outcomes rather than the quality of the clinical study.
The draft guideline went through a rigorous reviewing process, in which stakeholder organisations were invited to comment; the group took all comments into consideration when producing the final version of the guideline.
A formal review of the need to update a guideline is usually undertaken by NICE after its publication. NICE will conduct a review to determine whether the evidence base has progressed significantly to alter the guideline recommendations and warrants an update.
Cost effectiveness
A new cost effectiveness analysis was undertaken from an NHS and Personal Social Services perspective to compare decision rules on when anticoagulation should be given. The analysis focused on the low stroke risk groups, where uncertainty about when anticoagulation may be appropriate is most uncertain, given the risk of bleeding on this therapy. Where anticoagulation was not indicated by the decision rule, the analysis compared three alternative treatment options: single antiplatelet therapy, dual antiplatelet therapy, and a do nothing approach. The compared decision rules were based on the CHADS 2 score, the CHA 2 DS 2 -VASc score, and the HAS-BLED score. Combinations of stroke and bleeding risk thresholds using these scores were compared to determine when anticoagulation should be given.
The analysis used and adapted an existing and validated discrete event time simulation model. 18 The analysis suggests that, of the decision rules compared, the highest net monetary benefit was most likely to be achieved when anticoagulation was offered at a CHA 2 DS 2 -VASc score of 2 or above, with a do nothing approach below this risk score. There is only a slightly lower probability that an offer of anticoagulation at a CHA 2 DS 2 -VASc score of 1 would be the optimal strategy. The analysis also suggested that once the patient achieves a HAS-BLED score of 1 or more, the risks of bleeding should be taken into account.
Future research
The GDG identified some priority areas for research:
• What is the clinical and cost effectiveness of cognitive behavioural therapy compared with usual care for people with newly diagnosed atrial fibrillation?
• What is the comparative effectiveness of the three main drug classes used for rate control (β blockers, calcium channel blockers, and digoxin) in people aged 75 years or more with atrial fibrillation in controlling symptoms, improving quality of life, and reducing morbidity and mortality?
• What is the effect of case volume on complications and outcomes after left atrial catheter ablation?
• Do people with atrial fibrillation whose anticoagulant control with warfarin is poor, or is predicted to be poor, benefit from changing to one of the non-vitamin K antagonist oral anticoagulants?
• Can routine data from UK primary care databases clarify stroke risk in people with atrial fibrillation according to baseline risk factors and treatment? Tables   Table 1| CHA2DS2 
